Recursion

Recursion: AI Drug Discovery Platform

Recursion is the public AI drug discovery company ($RXRX) on a mission to industrialize drug discovery via phenomic imaging at scale: capturing millions of cellular images, training ML models on the morphological signatures of disease + treatment response, and using the resulting maps to identify drug candidates faster than traditional methods. Operates BioHive, one of the largest pharma-owned supercomputers, in partnership with Nvidia.

Merged with Exscientia in 2024 to combine phenomics with structure-based drug design — creating one of the most well-resourced AI biotech platforms.

Key Features

• Phenomic imaging — millions of cellular images per week
• ML maps biology + chemistry interactions at scale
• BioHive supercomputer (Nvidia-powered)
• Merged with Exscientia 2024 — phenomics + structure
• Public on Nasdaq ($RXRX)

Ideal Use Case

Pharmaceutical companies seeking AI partners for drug discovery — particularly programs in disease areas where phenotypic screening adds signal beyond target-based approaches. Also relevant for biotech investors tracking AI drug discovery progress.

Why Use Recursion

AI drug discovery is crowded but Recursion has consolidated scale (Nvidia partnership, supercomputer ownership, public-market capital). Post-Exscientia merger they cover both phenomics and structure-based drug design.

FAQ

Q: Public? A: Yes — Nasdaq: $RXRX.

Q: Pipeline? A: Multiple clinical programs across rare diseases, oncology, fibrosis, and more.

Q: Why phenomics? A: Captures cell-level treatment response without needing a known target — surfaces unexpected mechanisms.

tl;dr

Public AI drug discovery ($RXRX). Phenomics + ML at industrial scale. Merged with Exscientia 2024.

Related

Looking for more options? Browse the Healthcare directory or read our best AI healthcare tools listicle. Recursion is also tracked on Crunchbase.